Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040

Patent ExpiryBreast Cancer VaccinePositive

AI Analysis

Summary

Anixa Biosciences secured a composition of matter patent for its breast cancer vaccine in Australia with exclusive protection through 2040. The patent grant expands the company's global intellectual property estate in markets with increasing breast cancer incidence.

Outcome Details

Composition of matter patent granted in Australia with protection through 2040

Importance:4/10

Sentiment:

0.60

patentintellectual propertybreast cancervaccineAustraliaglobal expansion

Related Companies

$ANIX

Read the original article

Published by PR Newswire Pharma on September 21, 2026 12:45 PM

Read Original